JP2025069432A5 - - Google Patents
Info
- Publication number
- JP2025069432A5 JP2025069432A5 JP2025019263A JP2025019263A JP2025069432A5 JP 2025069432 A5 JP2025069432 A5 JP 2025069432A5 JP 2025019263 A JP2025019263 A JP 2025019263A JP 2025019263 A JP2025019263 A JP 2025019263A JP 2025069432 A5 JP2025069432 A5 JP 2025069432A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- region
- variable region
- seq
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913744P | 2019-10-11 | 2019-10-11 | |
| US62/913,744 | 2019-10-11 | ||
| JP2022522002A JP7634001B2 (ja) | 2019-10-11 | 2020-09-30 | ４－１ｂｂに結合する抗体およびその用途 |
| PCT/CN2020/119388 WO2021068841A1 (en) | 2019-10-11 | 2020-09-30 | Antibodies binding 4-1bb and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522002A Division JP7634001B2 (ja) | 2019-10-11 | 2020-09-30 | ４－１ｂｂに結合する抗体およびその用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025069432A JP2025069432A (ja) | 2025-04-30 |
| JP2025069432A5 true JP2025069432A5 (https=) | 2025-10-06 |
Family
ID=75382666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522002A Active JP7634001B2 (ja) | 2019-10-11 | 2020-09-30 | ４－１ｂｂに結合する抗体およびその用途 |
| JP2025019263A Pending JP2025069432A (ja) | 2019-10-11 | 2025-02-07 | ４－１ｂｂに結合する抗体およびその用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522002A Active JP7634001B2 (ja) | 2019-10-11 | 2020-09-30 | ４－１ｂｂに結合する抗体およびその用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11466086B2 (https=) |
| EP (1) | EP4041772A4 (https=) |
| JP (2) | JP7634001B2 (https=) |
| CN (2) | CN117586400A (https=) |
| WO (1) | WO2021068841A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466086B2 (en) * | 2019-10-11 | 2022-10-11 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1BB and uses thereof |
| CN118684772A (zh) * | 2021-09-09 | 2024-09-24 | 广东东阳光药业股份有限公司 | 抗4-1bb的激动型抗体及其应用 |
| WO2023168547A1 (en) * | 2022-03-07 | 2023-09-14 | Adagene Pte. Ltd. | Anti-cd137 antibodies and methods of making and using the same |
| EP4584300A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Multispecific constructs and uses thereof |
| JP2026508244A (ja) | 2023-02-22 | 2026-03-10 | ナンジング リーズ バイオラブズ シーオー．， エルティーディー． | 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体 |
| WO2025067330A1 (zh) * | 2023-09-27 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | 用于治疗肿瘤的抗pd-l1和抗4-1bb双特异性抗体 |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2026061538A1 (zh) * | 2024-09-23 | 2026-03-26 | 南京维立志博生物科技股份有限公司 | 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| JP2018520650A (ja) * | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | 新規のポリペプチド |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112019005895A2 (pt) * | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| IL268836B2 (en) * | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN111194323B (zh) | 2017-10-10 | 2024-07-09 | 努玛治疗有限公司 | 多特异性抗体 |
| EP3470426A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| TWI701259B (zh) | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| CA3100119A1 (en) | 2018-07-31 | 2020-02-06 | Pieris Pharmaceuticals Gmbh | Fusion protein specific for cd137 and pd-l1 |
| CN109021107B (zh) | 2018-09-05 | 2020-08-28 | 江苏诺迈博生物医药科技有限公司 | 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒 |
| CN119798453A (zh) | 2018-11-13 | 2025-04-11 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| CN113286825B (zh) | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| US11466086B2 (en) * | 2019-10-11 | 2022-10-11 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1BB and uses thereof |
-
2020
- 2020-09-30 US US17/038,669 patent/US11466086B2/en active Active
- 2020-09-30 CN CN202311290309.4A patent/CN117586400A/zh active Pending
- 2020-09-30 EP EP20875286.5A patent/EP4041772A4/en active Pending
- 2020-09-30 CN CN202080071050.2A patent/CN114555638B/zh active Active
- 2020-09-30 WO PCT/CN2020/119388 patent/WO2021068841A1/en not_active Ceased
- 2020-09-30 JP JP2022522002A patent/JP7634001B2/ja active Active
-
2022
- 2022-10-07 US US18/045,133 patent/US20230192862A1/en active Pending
-
2025
- 2025-02-07 JP JP2025019263A patent/JP2025069432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025069432A5 (https=) | ||
| Christiansen et al. | Biological impediments to monoclonal antibody–based cancer immunotherapy | |
| JP2025163055A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2019507135A5 (https=) | ||
| JPWO2021155380A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2017186337A5 (https=) | ||
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| JP2020517239A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2024016024A5 (https=) | ||
| JP2020533004A5 (https=) | ||
| JP2005532051A5 (https=) | ||
| JP2024020436A5 (https=) | ||
| JP2026015500A5 (https=) | ||
| JPWO2021068841A5 (https=) | ||
| JPWO2022114163A5 (https=) | ||
| JPWO2022104236A5 (https=) | ||
| JPWO2022068854A5 (https=) | ||
| JP7604452B2 (ja) | 結合メンバー |